Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HCL-PG04: step-wise combination of obinutuzumab, vemurafenib, and cobimetinib in BRAF-V600E mutated hairy cell leukemia
2017-001836-20Phase 2Active
- Sponsor
- PROF.BRUNANGELO FALINI, DR.ENRICO TIACCI. DIPARTIMENTO DI MEDICINA, UNIVERSITA' DI PERUGIA
- Start
- Mar 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obinutuzumab, vemurafenib and cobimetinib in hairy cell leukemia (HCL), sponsored by PROF.BRUNANGELO FALINI, DR.ENRICO TIACCI. DIPARTIMENTO DI MEDICINA, UNIVERSITA' DI PERUGIA. Primary endpoints: Response rate by cohort and Response rate by intention-to-treat analysis. Started Mar 2021; status: active.
02
Drugs
obinutuzumabvemurafenibcobimetinib
03
Conditions
hairy cell leukemia (HCL)
Beyond the preview
Go deeper on 2017-001836-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001836-20.